ArticleTherapeutics and clinical risk management2025

The Higher Incidence of Liver Injury in HCC Patients Compared to Other Malignancies During Immune-Checkpoint Inhibitor Therapy is Primarily Due to Tumor Progression.

Yan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.